Share ownership Incyte Corporation

INCY

US45337C1027

Pharmaceuticals

Real-time Estimate Cboe BZX Other stock markets 02:30:49 17/07/26 am AEST			5-day change	1st Jan Change
115.88 ^USD	+0.69%		-2.08%	+17.51%

15/07	BofA Securities Raises Incyte Price Target to $136 From $124	MT
14/07	Barclays Adjusts Incyte Price Target to $134 From $117, Maintains Overweight Rating	MT

Share class: Incyte Corporation

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	199,782,155	195,994,556 ( 98.1 %)	0	98.1 %

Major shareholders: Incyte Corporation

Name	Stocks	%	Valuation
Baker Bros. Advisors LP 15.54 %	31,040,841	15.54 %	3 519 M $
Baker Bros. Advisors LP 15.39 %	30,744,412	15.39 %	3 485 M $
BlackRock Advisors LLC 7.293 %	14,570,131	7.293 %	1 652 M $
Dodge & Cox 6.133 %	12,252,356	6.133 %	1 389 M $
Vanguard Capital Management LLC 5.471 %	10,930,066	5.471 %	1 239 M $
STATE STREET CORPORATION 4.826 %	9,641,384	4.826 %	1 093 M $
Vanguard Portfolio Management LLC 3.884 %	7,759,183	3.884 %	880 M $
AQR Capital Management LLC 2.907 %	5,807,930	2.907 %	658 M $
Geode Capital Management LLC 2.354 %	4,703,184	2.354 %	533 M $
BlackRock Life Ltd. 2.007 %	4,010,584	2.007 %	455 M $
░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░
░░░░░░░░░░░░░░░░░░░	░ ░░░	░░░░%	░░

Breakdown by shareholder type

Institutional	107.6%
Others	7.67%
State Street Corp.	4.83%
Individuals	0.87%
SEI Investments Co.	0.38%
Schweizerische Nationalbank	0.25%
Sumitomo Mitsui Trust Group, Inc.	0.21%
Swedbank AB	0.18%
Governments	0.14%
Manulife Financial Corp.	0.06%
Danske Bank A/S	0.04%
Northwest Bancshares, Inc. (Pennsylvania)	0.03%
Banco Bilbao Vizcaya Argentaria SA	0.02%
The Bank of Nova Scotia	0.01%
Fifth Third Bancorp	0.01%
Hennessy Advisors, Inc.	0.01%
The Allstate Corp.	0.01%

Based on 1000 largest holdings

Geographical origin of shareholders

United States	99.85%
United Kingdom	7.39%
Australia	2.99%
Canada	2.89%
Netherlands	1.43%
France	1.15%
Sweden	1.06%
Switzerland	1.01%
Norway	0.98%
Individuals	0.87%
Japan	0.61%
Luxembourg	0.33%
Denmark	0.33%
Ireland	0.3%
Germany	0.26%
Italy	0.19%
South Korea	0.15%
Belgium	0.1%
Spain	0.08%
Puerto Rico	0.06%
New Zealand	0.06%
South Africa	0.04%
Hong Kong	0.04%
China	0.04%
Finland	0.03%
Czech Republic	0.02%
Austria	0.02%
Taiwan	0.01%
Mexico	0.01%
Liechtenstein	0.01%
Brazil	0.01%

Based on 1000 largest holdings

Incyte Corporation specializes in the research & development of therapeutic products mainly intended for the treatment of cancers and inflammatory disorders. Net sales break down by revenue source as follows: - product sales (84.7%); - royalties (12.4%); - income from research and cooperation agreements (2.9%).

Employees

2,844

Sector

Pharmaceuticals

Calendar

28/07 - Earnings release - Q2 2026

More about the company